Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Cynosure Recognized as One of FORTUNE's 100 Fastest-Growing Companies

Posted on: 30 Sep 16

WESTFORD, Mass., Sept. 30, 2016 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today announced that it has been named to FORTUNE's 2016 list of "100 Fastest-Growing Companies." Cynosure ranked 30th on the prestigious list, which identifies the top public companies based on three-year revenue growth, EPS growth and total return.      

"Our financial and operational performance over the past three years is a result of a disciplined strategy centered on innovative technology, high-quality products, global distribution and outstanding customer support," said Michael Davin, Cynosure's President and CEO. "At the core of this strategy are our employees. Their hard work and dedication have helped establish Cynosure as a premier aesthetic brand among physicians and patients. This is our inaugural year on FORTUNE's annual Fastest-Growing Companies list, and I want to congratulate the entire Cynosure team on this outstanding achievement." 

FORTUNE magazine's 100 Fastest-Growing Companies are publicly traded companies ranked by revenue growth rate, EPS growth rate, and three-year annualized total return for the period ended June 30, 2016. The overall rank is based on the sum of these three ranks.

For more information on Cynosure's ranking click here.

For additional information and the complete FORTUNE list click here.

About Cynosure, Inc.

Cynosure develops, manufactures, and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through non-invasive and minimally invasive laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecological health. Cynosure also markets radiofrequency energy-sourced medical devices for precision surgical applications such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, Q-switched lasers, intense pulsed light and radiofrequency technology. Cynosure sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names through a direct sales force in the United States, Canada, France, Morocco, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.  For corporate or product information, visit Cynosure's website at


Scott Solomon 
Senior Vice President 
Sharon Merrill Associates, Inc. 

For more information:

Editor's Details

Mike Wood

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.